Publicacións nas que colabora con Antonio Oliver Palomo (61)

2024

  1. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 5

  2. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 69-77

  3. In vitro activity of cefiderocolagainst European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations

    Microbiology Spectrum, Vol. 12, Núm. 8

2023

  1. Corrigendum: CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3(Front. Microbiol., (2022), 13, (918362), 10.3389/fmicb.2022.918362)

    Frontiers in Microbiology

  2. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 6, pp. 360-370

  3. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200

2022

  1. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815

  2. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

    Frontiers in Microbiology, Vol. 13

  3. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

    Microbiology spectrum, Vol. 10, Núm. 5, pp. e0292722

  4. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3163-3172

  5. Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software

    Frontiers in Microbiology, Vol. 12

  6. Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

2021

  1. 6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam Antibiotics

    Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 6310-6328

  2. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 2, pp. 370-379

  3. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 6, pp. 1474-1478

2020

  1. Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 2

  2. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

    Scientific Reports, Vol. 10, Núm. 1

  3. Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 11, pp. 3209-3217

  4. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

  5. Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274)

    Frontiers in Microbiology, Vol. 11